CD274 and non-small cell lung carcinoma: Anti-PD-L1 has been used to treat NSCLC patients having no mutations in epidermal growth factor receptor (EGFR) or in anaplastic lymphoma kinase (ALK) and has a significant upregulated expression of PD-L1 and PD-L2.